Fecal microbiota transplantation: A practical update for the infectious disease specialist

Clinical Infectious Diseases

Volumn 58, Issue 4, 2014, Pages 541-545

  Moore, Thomas ^a   Rodriguez, Andres ^b   Bakken, Johan S ^c  

^a Infectious Disease Consultants   (United States)

^b Infectious Diseases Society of America   (United States)

^c St Luke's Hospital   (United States)

Author keywords

Clostridium difficile; diarrhea; fecal microbiota transplantation; recurrent

Indexed keywords

METRONIDAZOLE; PREBIOTIC AGENT; PROBIOTIC AGENT; VANCOMYCIN; NEW DRUG;

ANTIBIOTIC THERAPY; ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; COLON FLORA; DETERIORATION; EXPERIMENTAL THERAPY; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HOSPITAL PHARMACY; HUMAN; MEDICAL RESEARCH; MEDICAL SPECIALIST; NONHUMAN; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; DRUG APPROVAL; FECES; GASTROINTESTINAL DISEASES; MICROBIOLOGY; PROCEDURES; UNITED STATES;

BIOLOGICAL THERAPY; DRUGS, INVESTIGATIONAL; FECES; GASTROINTESTINAL DISEASES; HUMANS; INVESTIGATIONAL NEW DRUG APPLICATION; UNITED STATES;

EID: 84893235395     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit950     Document Type: Article

References (13)

1. Miller BA, Chen LF, Sexton DJ, Anderson DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011; 32:387-90.
2. Dubberke ER, Butler AM, Yokoe DS, et al. Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol 2010; 31:1030-7.
3. McDonald LC, Lessa F, Sievert D, et al. Vital signs: central lineassociated blood stream infections-United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep 2011; 60:243-8.
4. Ghantoji SS, Sail K, Lairson DR, Dupont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74:309-18.
5. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficileassociated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med 1986; 146:95-100.
6. Adamu BO, Lawley TD. Bacteriotherapy for the treatment of intestinal dysbiosis caused by Clostridium difficile infection. Curr Opin Microbiol 2013; 16:596-601.
7. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368:407-15.
8. Eiseman B, SilenW, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44: 854-9.
9. Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009; 15:285-9.
10. Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent Clostridium difficile infection: Report on a case series. Anaerobe 2012; 19:22-6.
11. Bakken JS, Borody T, Brandt LJ, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9:1044-9.
12. Petrof EO, Gloor GB, Vanner SJ, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: "RePOOPulating" the gut. Microbiome 2013; 1:3-10.
13. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108:1367.